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Abstract 
Recently the American Society of Clinical Oncology and the College of American Pathologists have 
updated their clinical practice guidelines for HER2 testing in breast cancer. In order to evaluate 
these new recommendations, we have re-assessed the HER2 status of 6018 breast cancer cases of 
the screening population for the HERceptin adjuvant (HERA) trial that were originally centrally 
tested by fluorescence in situ hybridization based on the FDA-released test guidelines. According to 
the most recent 2013 ASCO/CAP recommendations, 3380 (56.2%) cases were classified as HER2 
positive compared with 3359 (55.8%) applying the HERA/FDA scheme and 3339 (55.5%) applying 
the 2007 ASCO/CAP guidelines. Twenty-one cases switched from negative (HERA/FDA scheme) 
to positive (2013 ASCO/CAP guidelines). This group is characterized by a mean HER2 gene copy 
number of ≥6.0, polysomy or co-amplification of CEP17 with an average CEP17 count of 5, and 
with HER2 receptor overexpression in 75% of cases. On the basis of the HER2 gene copy number 
alone, we observe 494 cases (8.2%) that are in the equivocal range. Most of these cases (>80%) 
were also nondecisive by immunohistochemistry (score 2+) irrespective of whether ratio was . The 
number of equivocal cases that would require HER2 reflex testing decreases to 113 (1.9%) if in 
addition to the HER2 gene copy number also the ratio of HER2 and CEP17 copy numbers is 
considered via dual-color in situ hybridization. The combination of applying the HER2 mean gene 
copy number as well as the HER2/CEP17 ratio to define equivocal test decisions by fluorescence in 
situ hybridization as proposed by the current ASCO/CAP guidelines appears to be a more optimum 
approach to adopt in order to avoid or minimize reporting of false negative results. Using the mean 
HER2 gene copy number alone for decision making results in a significant increase of equivocal 
cases. 
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